ripekg:evaluation/RIPEA2D330616160C50F0 |
prov:wasInformedBy |
ripekg:evidence-aggregation/RIPEA2D330616160C50F0 |
ripekg:evidence-aggregation/RIPEA2D330616160C50F0 |
rdf:type |
rdfs:Resource |
ripekg:evidence-aggregation/RIPEA2D330616160C50F0 |
rdf:type |
owl:Thing |
ripekg:evidence-aggregation/RIPEA2D330616160C50F0 |
rdf:type |
ripe:EvidenceAggregationEvidence aggregation |
ripekg:evidence-aggregation/RIPEA2D330616160C50F0 |
rdf:type |
tido:Activity |
ripekg:evidence-aggregation/RIPEA2D330616160C50F0 |
prov:startedAtTime |
2026-04-05T15:50:01.226082Z |
ripekg:evidence-aggregation/RIPEA2D330616160C50F0 |
prov:wasAssociatedWith |
ripekg:automated-agent/inspect-ai/1.0.0INSPECT-AI 1.0.0 |
ripekg:evidence-aggregation/RIPEA2D330616160C50F0 |
prov:wasAssociatedWith |
ripekg:automated-agent/inspect-ai/1.0.0INSPECT-AI |
ripekg:evidence-aggregation/RIPEA2D330616160C50F0 |
tido:contributesTo |
ripekg:research-integrity-assessment/RIPEA2D330616160C50F0 |
ripekg:publication-details/RIPEA2D330616160C50F0Effect of curcumin nanomicelle on the clinical symptoms of patients with rheumatoid arthritis: A randomized, double‐blind, controlled trial |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA2D330616160C50F0 |
ripekg:registry-evidence/RIPEA2D330616160C50F0 |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA2D330616160C50F0 |
ripekg:study-design-evidence/RIPEA2D330616160C50F0 |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA2D330616160C50F0 |